Next year, doctors might finally have something new to offer people who suffer from schizophrenia: a much-needed drug that can better improve their symptoms without the side effects that too often cause them to stop taking their medications.
The latest round of late-stage data on a drug in development by Karuna Therapeutics, released recently, reinforces its potential to offer desperately needed progress for a brain disorder that affects about 1% of people in the U.S.
Karuna’s news is a bit of a revival story. One component of the treatment, called xanomeline, has been around since the early 1990s, when scientists at Eli Lilly & Co. started exploring its use to treat the cognitive and behavioral symptoms of Alzheimer’s disease and, later, schizophrenia.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.